Sinopharm Group Co. Ltd. (OTCMKTS:SHTDY – Get Free Report) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 45,536 shares, an increase of 239.8% from the May 31st total of 13,400 shares. Based on an average daily trading volume, of 240,411 shares, the short-interest ratio is currently 0.2 days.
Sinopharm Group Stock Performance
Shares of OTCMKTS:SHTDY traded up $0.10 during trading on Monday, reaching $10.24. 10,425 shares of the company were exchanged, compared to its average volume of 80,551. The business’s fifty day simple moving average is $11.33 and its 200-day simple moving average is $12.53. Sinopharm Group has a 12-month low of $10.00 and a 12-month high of $14.87.
Sinopharm Group Company Profile
Sinopharm Group Co, Ltd. (OTCMKTS:SHTDY) is one of China’s largest integrated healthcare companies and an indirect subsidiary of the state-owned China National Pharmaceutical Group Co, Ltd. The company operates through two primary segments—pharmaceutical distribution and retail pharmacy—offering comprehensive supply chain solutions that span procurement, storage, transportation and sales of medical products. With a broad portfolio that includes prescription drugs, over-the counter medicines, medical devices and consumables, Sinopharm serves hospitals, clinics, retail pharmacies and other healthcare institutions across mainland China.
In its distribution business, Sinopharm leverages an extensive logistics network, comprising hundreds of distribution centers and thousands of delivery vehicles, to ensure timely delivery of pharmaceuticals under stringent temperature-controlled conditions.
Featured Articles
- Five stocks we like better than Sinopharm Group
- Is McCormick a Steal Ahead of Game-Changing Unilever Deal?
- Qualcomm’s Investor Day Just Changed the Growth Story Forever
- JPMorgan Stands by Sky-High Broadcom Target as Shares Slide
- 5 Places Investors Can Hide If the AI Trade Keeps Cracking
Receive News & Ratings for Sinopharm Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinopharm Group and related companies with MarketBeat.com's FREE daily email newsletter.
